10 Stocks That Tanked: Why Larry Robbins’ Top Picks Are Struggling in 2026

8. Myriad Genetics, Inc. (NASDAQ:MYGN)

YTD Decline in Share Price: 18%

Glenview Capital’s Stake: $28 million 

Myriad Genetics, Inc. (NASDAQ:MYGN) has been a staple in the 13F portfolio of Glenview Capital since the third quarter of 2019. Back then, this position comprised 3.6 million shares. Since then, the fund has trimmed or increased this holding on a periodic basis. At one point in 2023, this position comprised close to 5.3 million shares. Filings for the fourth quarter of 2025 show that the fund owned almost 4.6 million shares in the firm, the same as in the previous quarter. Myriad is a molecular diagnostics and precision medicine company that develops molecular tests. It offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics.

Myriad Genetics, Inc. (NASDAQ:MYGN) has been unable to sway Wall Street despite years of restructuring. In Q1 2026, the firm reported a GAAP net loss of $34.1 million. Critics argue that if the company couldn’t find a path to profit during the height of the genetic testing boom, it is unlikely to do so now as competition intensifies. The bears also argue that the firm is losing share of wallet in the broader molecular diagnostics space. 12-month revenue growth of 5.7% significantly trails the US market average of 11.3%. Analysts at TD Cowen and Wells Fargo recently lowered their price targets on the stock following the Q1 miss.

READ ALSO: 15 Under-the-Radar Picks from David Einhorn That Are Quietly Dominating 2026.